1 Canadian Stock up 30% in a Month and Climbing

Bausch Health (TSX:BHC)(NYSE:BHC) stock is climbing back with the separation of its Bausch + Lomb shares looking imminent.

| More on:
Business success with growing, rising charts and businessman in background

Image source: Getty Images

Bausch Health (TSX:BHC)(NYSE:BHC) has seen shares climbed by over 30% in the last month alone. At a time when the TSX continues to trade down by 8.55% year to date, Bausch Health stock seems to be on the increase. However, shares are still down by 73% year to date.

Today, I’m going to look at why this sudden increase in share price has been going on, and whether it means Canadians should consider buying the stock.

Separation anxiety

The catalyst for growth seems to be related to Bausch Health stock’s separation of its Bausch + Lomb company. The process continues to be underway, but the company continues to work through patent litigation so that it can separate the distribution of its Bausch + Lomb shares.

On top of this, the company announced in its second-quarter results that its balance sheet continues to improve, and it’s moving forward with an appeal of a patent dispute. More recently, there was also a tentative approval of Bausch Health stock’s rifaximin drug for traveler’s diarrhea by the Food and Drug Administration (FDA) of the United States.

Still, the biggest piece seems to be the Bausch + Lomb separation. As of Aug. 30, 23% of existing senior note holders agreed to hand over their notes for secured senior notes. While we’re still waiting for the holdout, it seems like there is progress being made.

Revenue improvement needed

One of the biggest factors for the separation comes down to managing the company’s debt, and, as of the latest quarter, it doesn’t look too great. The second quarter saw Bausch Health stock report US$145 million. While this is still a fairly large loss, it’s a massive improvement from the loss of US$595 million a year before. Still, revenue was down to US$1.97 billion from US$2.1 billion the year before.

Given this information, Bausch Health stock updated its year-end guidance, with revenue expected to be between US$8.05 billion and US$8.22 billion. This is down from the US$8.25 billion and US$8.4 billion expected before. Yet when you look at how Bausch + Lomb performs, it’s great news. The company reported revenue of US$941 million for the second quarter, which was up from US$934 million in 2021.

Experts are in

Pretty much everyone supports the separation of these companies, with Bausch + Lomb able to focus on its eye health line, and Bausch Health stock able to focus on its continued debt reduction. Analysts, in fact, have continued to raise their price targets for the stock, as the separation looks more likely.

One analyst expects the net debt to decline by $2.9 billion if Bausch Health stock is successful in this debt exchange. “This should pave the way for 50.1% distribution of BLCO shares to BHC shareholders.”

Worth the risk?

As mentioned, shares of Bausch Health stock are still down by 73% year to date, even with this 30% growth. It also still trades at 52.72 times earnings as of writing. So, while there’s some reason to buy the stock, it remains an incredibly risky buy. It’s up to you and your risk tolerance on whether you’re willing to take it on.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Investing

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

3 Canadian Dividend Stocks to Buy Hand Over Fist

These three Canadian dividend stocks each offer a unique opportunity, making them some of the best investments to buy at…

Read more »

Chalk outline of two arrows pointing in opposite directions
Top TSX Stocks

2 TSX Stocks That Can Deliver Massive Gains in a Recession

Restaurant Brands International (TSX:QSR)(NYSE:QSR) stock and another recession-resilient firm that can win big in 2023.

Read more »

Growing plant shoots on coins
Stocks for Beginners

For New (and Old) Investors: 3 Dividend-Paying ETFs With Lower-Risk Profiles

Three dividend-paying ETFs with lower-risk profiles are suitable for new and old investors alike.

Read more »

Hand holding smart phone with online shop concept on screen
Tech Stocks

Is Now the Time to Buy Shopify Stock?

Shopify stock (TSX:SHOP)(NYSE:SHOP) hasn't hit these lows in years. So is it a great time to buy the dip, or…

Read more »

A person builds a rock tower on a beach.
Dividend Stocks

Retirement Wealth: 2 Oversold Canadian Stocks to Buy Now and Own for Decades

These industry-leading dividend stocks look cheap right now and have increased their distributions annually for decades.

Read more »

money cash dividends
Tech Stocks

Got $1,000? 3 Cheap Stocks to Buy Right Now

If you've got cash on the sidelines that you're looking to put to work, here are three cheap stocks that…

Read more »

Tired or stressed businessman sitting on the walkway in panic digital stock market financial background
Dividend Stocks

2 of the Safest TSX Stocks Right Now

The stock market is heading towards a crash. Investors are seeking the safety of dividends, and these two stocks provide…

Read more »

question marks written reminders tickets
Tech Stocks

Nvidia Stock Is Down 60%: Should You Buy?

Nvidia (NASDAQ:NVDA) stock has slipped over 60% as short-term headwinds hurt its revenue. But a long-term view of the stock…

Read more »